Quinine: Difference between revisions
(Restore original dosing content alongside dynamic SMW tables) |
(Remove disease-specific entries now covered by AntibioticDose (8 sections)) |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 36: | Line 21: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 11:08, 20 March 2026
Administration
- Type: Atypical antipsychotic
- Dosage Forms: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; 1mg/mL
- Routes of Administration: Oral, IM
- Common Trade Names: Risperdal
Adult Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Babesiosis | 650mg TID | Severe parasitemia with Clindamycin use IV for severe |
| Malaria | 648mg PO q8h x 7 days | Uncomplicated malaria, use with doxycycline or clindamycin |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Babesiosis | 8mg/kg PO q8h x 7-10 days (Max: 648mg/dose) | Severe parasitemia with Clindamycin |
| Malaria | 30mg/kg/day PO q8h x 3-7 days (Max: 648mg/dose) | Uncomplicated malaria, use with clindamycin |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal:
- Adult:
- CrCl <30: Start 0.5 mg BID then increase by 0.5mg BID weekly
- HD: Not defined
- Pediatric:
- Not defined, see adult dosing.
- Adult:
- Hepatic:
- Adult:
- Child-Pugh Class C: Start 0.5 mg BID and increase by 0.5mg BID weekly
- Pediatric:
- Not defined, see adult dosing.
- Adult:
Contraindications
- Allergy to class/drug
- Caution:
- Pediatric/adolescent pts
- Pregnancy 3rd trimester
- Elderly pts
- Dementia-related psychosis
- Renal impairment
- Hepatic impairment
- Parkinson's Disease
- Neuroleptic malignant syndrome history
- Seizure history
- Cardiovascular disease
- Diabetes mellitus
- Suicide risk
Adverse Reactions
Serious
- Hypotension, syncope
- Extrapyramidal symptoms: tardive dyskinesia
- Neuroleptic malignant syndrome, hyperthermia
- Hyperglycemia, diabetes mellitus, DKA
- Seizure, Priapism, Stroke, TIA
- Dysphagia
- Leukopenia, Neutropenia, Agranulocytosis
- Suicidality
- Pancreatitis
Common
- Akathisia, dystonia, parkinsonism, tremor
- Sedation/fatigue, dizziness, blurred vision, anxiety, confusion
- Rash
- Hyperprolactinemia, weight gain, increased appetite
- Constipation, diarrhea, nausea/vomiting
- Urinary incontinence
- Cough, URI
- Photosensitivity, visual disturbance
Pharmacology
- Half-life: 20h (PO); 3-6 day (IM)
- Metabolism: Hepatic, CYP2D6
- Excretion: Urine 70%, Feces 14%
Mechanism of Action
- Unknown
- 5HT-2 inhibitor, weaker D2 inhibitor